Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

Public Disclosure Bar and Pleading Deficiencies Doom Tennessee FCA Case

By Brian Roark on April 23, 2020
Email this postTweet this postLike this postShare this post on LinkedIn

On February 25, the U.S. District Court for the Western District of Tennessee dismissed a relator’s qui tam False Claims Act (FCA) suit alleging that the defendants had continued the “exact scheme” previously alleged in U.S. ex rel. Deming v. Jackson-Madison Cty. Gen. Hosp., et al. involving allegations of medically unnecessary cardiac testing and procedures.

The defendants in U.S. ex rel. Maur v. Cmty. Health Sys., Inc., et al., represented by Bass, Berry & Sims and others, moved to dismiss the relator’s action on two grounds.  First, the defendants argued that the FCA’s public disclosure bar prohibited the relator’s action as the lawsuit raised substantially the same allegations as those publicly disclosed in the Deming action and subsequent press releases related to that lawsuit.  Second, the defendants maintained that the relator had failed to plead any FCA claims with the requisite particularity under Federal Rule of Civil Procedure 9(b).  The district court granted the defendants’ motions and dismissed the relator’s action on both grounds.

FCA’s Public Disclosure Bar Precludes Relator’s Action Alleging the “Same” Scheme Previously Disclosed in Prior Lawsuit

The FCA’s public disclosure bar prohibits a relator’s action when an earlier public disclosure of fraud reveals substantially similar allegations of fraud as that alleged in the relator’s action unless the relator qualifies as an “original source” of the allegations.  The district court in Maur determined that the public disclosure bar applied using a three-part analysis:

  • First, the court held the Deming action and subsequent press releases constituted public disclosures of the fraudulent conduct alleged by the relator.
  • Second, the court concluded that the Deming action and press releases disclosed substantially the same allegations as those asserted by the relator. The court reasoned that, although the relator’s action involved some defendants and patient examples that differed from the Deming action, the relator alleged “the same fraudulent scheme” already disclosed in the Deming action and that the relator even lifted “phrases verbatim from the Deming ”
  • Third, the court ruled that the relator did not qualify as an “original source” of the information in his complaint. The relator merely restated the scheme previously disclosed in the Deming action and, therefore, did not materially add to the information publicly disclosed by that action.

Complaint Fails to Plead Fraud with Particularity as Required by Federal Rule of Civil Procedure 9(b)

In addition to concluding that the public disclosure bar prohibited the relator’s action, the court also ruled that the relator’s complaint contained numerous pleading deficiencies dooming his case.  The relator failed to identify with particularity any false claim that was submitted to the government for payment pursuant to the alleged fraudulent scheme.  Although the relator also asserted a “reverse false claim” allegation under the FCA, he omitted allegations of any obligation that the defendants owed to the government as required to plead a reverse false claim.  Finally, although he alleged an FCA conspiracy, the relator pleaded none of the requisite elements of a conspiracy claim.  Thus, in addition to pleading allegations of fraud that previously were publicly disclosed, the district court held that the relator failed to provide specific factual allegations to support any of his FCA claims with the requisite particularity required under Rule 9(b).  The relator’s qui tam complaint was dismissed in its entirety.

For a summary of recent developments regarding the public disclosure bar and other updates on the FCA, contact a member of Bass, Berry & Sims Healthcare Fraud Task Force, or download our Healthcare Fraud & Abuse Annual Review.

Photo of Brian Roark Brian Roark

Brian Roark is co-chair of the Bass, Berry & Sims Healthcare Fraud Task Force and concentrates his practice on representing healthcare clients in responding to governmental investigations and defending False Claims Act lawsuits. He has successfully litigated and resolved numerous healthcare fraud matters…

Brian Roark is co-chair of the Bass, Berry & Sims Healthcare Fraud Task Force and concentrates his practice on representing healthcare clients in responding to governmental investigations and defending False Claims Act lawsuits. He has successfully litigated and resolved numerous healthcare fraud matters involving hospitals and health systems, ambulatory surgery centers, hospices, home health companies, drug and alcohol abuse treatment centers, Medicare Advantage companies, and other healthcare providers.

Read more about Brian RoarkEmail
Show more Show less
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    Inside the False Claims Act
  • Organization:
    Bass, Berry & Sims PLC
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo